HER2/neuAmplification in Breast Cancer
Open Access
- 1 June 2002
- journal article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 117 (6) , 916-921
- https://doi.org/10.1309/4ntu-n6k4-f8jf-ewrx
Abstract
The presence of HER2/neu gene amplification is prognostically and therapeutically significant for patients with breast cancer. We sought to determineKeywords
This publication has 18 references indexed in Scilit:
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assaysJournal of Clinical Pathology, 2000
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999
- Overexpression of p53, c-erbB-2 and epidermal growth factor receptor in human breast carcinomasPathology International, 1996
- Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factorsInternational Journal of Cancer, 1991
- C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosisBritish Journal of Cancer, 1990
- c-erbB2 expression in correlation to other biological parameters of breast cancerZeitschrift für Krebsforschung und Klinische Onkologie, 1990
- Neu-Protein Overexpression in Breast CancerNew England Journal of Medicine, 1988
- The neu Gene: an erb B-Homologous Gene Distinct from and Unlinked to the Gene Encoding the EGF ReceptorScience, 1985
- Histological Grading and Prognosis in Breast CancerBritish Journal of Cancer, 1957